ARONTIER
ARONTIER is a Seoul-based AI-driven drug discovery company that combines physics-based modeling with machine learning to design antibodies, protein binders, small molecules, and RNA therapeutics for pharmaceutical, biotech, hospital, and academic partners.
- Company typePrivate
- Founded2018
- HeadquartersSeocho, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What ARONTIER does
ARONTIER (아론티어) is a Seoul-based, privately held AI-driven drug discovery company that integrates physics-based modeling with machine learning to design therapeutic candidates across multiple modalities, including antibodies, protein/peptide binders, peptidomimetics, small molecules, and personalized neoantigen mRNA cancer vaccines. The platform is organized into specialized modules — REMEDY for multiomics-based target and drug-repurposing discovery, Small Molecule Designer for generative hit identification, Protein Designer for antibody and binder engineering, RNA Designer for personalized cancer vaccines, Arontier PATH for digital-pathology tumor-microenvironment classification (MFDS approval in progress), and DeepComet for DNA-damage analysis — unified under the AD3 AI drug development platform (beta launched October 2022). The technical stack includes proprietary models AK-Score2, V-Dock, Docking of Millions (DoM), IgPose, and A-Prot, with published benchmarks such as ~12% screening time and 89% top-100 retrieval on 5M-compound libraries (DoM), top-1% enrichment factors of 32.7 and 23.1 on CASF2016/DUD-E, and 31+ peer-reviewed publications (2022–2026) in venues including Nature Communications, Briefings in Bioinformatics, Bioinformatics, J Cheminform, and Sci Rep; IgPose is additionally open-sourced on GitHub (arontier/igpose).
The business model is project-based and partnership-driven rather than SaaS/API: revenue streams comprise contract research and co-development fees from Korean and Chinese pharmaceutical and biotech companies, milestone and IP-sharing arrangements in joint research agreements, large Korean national R&D program grants, and strategic equity investment from corporate backers such as HLB Group (5 billion KRW in July 2024). Named enterprise and institutional customers include HLB Group and affiliates (BioStep, Panagine), Celltrion Pharm, Dongkook Pharmaceutical, Samjin Pharmaceutical, PharmAbcine, Organoid Sciences, Synthenta, Teragenbio, Future Medicine, Aijin, NexEye, Gradient Bioconvergence, Pharmexin, K-Medi Hub, Samsung Seoul Hospital, Yonsei University Medical Center, and the First Affiliated Hospital of Xinxiang Medical University. Pricing is not publicly disclosed, there is no public API or SDK, and the go-to-motion is enterprise field sales.
The company was founded in 2017/2018 (website copyright 2018) by Insuk Sohn (CSO) and Junsu Ko (CEO), is headquartered at 15F, 241, Gangnam-daero, Seocho-gu, Seoul, and has 11–50 employees. It has been selected as a 2025 Korean government Top-tier Startup, featured as one of three 'small giant' companies at BioKorea 2026, and was previously the lead company for the Korean national 2019 AI Drug Development Platform Construction Project, providing a foundation of non-dilutive government capital and academic collaboration with Seoul National University, Ulsan University, and KAIST.
ARONTIER firmographics
Firmographics- Name
- ARONTIER
- Legal name
- 아론티어 주식회사 (Arontier Co., Ltd.)
- Website
- https://arontier.co
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ARONTIER is a Seoul-based AI-driven drug discovery company that combines physics-based modeling with machine learning to design antibodies, protein binders, small molecules, and RNA therapeutics for pharmaceutical, biotech, hospital, and academic partners.
- Ownership category
- akta.pro rank
ARONTIER industry classification
Industry- Product category
- AI Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where ARONTIER is headquartered
LocationHeadquarters
- HQ city
- Seocho
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
ARONTIER business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Equity investment / capital raise: Receives strategic equity investment from corporate backers (e.g., 5 billion won investment from HLB Group announced 2024-07-02). This is a financing-related inflow rather than operating revenue, but indicative of strategic capital partnerships.
- Government R&D grants and national project funding: Receives funding from Korean national R&D programs (2019 AI Drug Development Platform program — ~11.25 billion KRW per project over 3 years; AI Data-driven Bio-Leading Technology Development program 2024; Next-generation ADC manufacturing national project 2025; Data Voucher program 2025). Funds awarded to Arontier as lead or participating organization.
- Joint research and co-development contracts with pharma/biotech: Generates revenue through joint research agreements, MOUs, and co-development contracts with pharmaceutical and biotech companies (e.g., Celltrion Pharm, Dongkook Pharmaceutical, Samjin Pharmaceutical, Synthenta, Pharmexin, Gradient Bioconvergence, PharmAbcine, Aijin, Future Medicine, Teragenbio, NexEye). These arrangements typically combine service fees, milestone payments, and IP sharing.
- Platform-as-a-Service / contract research services: Provides AI-based small molecule design and synthesis services for partners (e.g., Synthenta small molecule design and synthesis service) and offers technology-platform access for customer R&D programs. Model is project-based / contract research rather than off-the-shelf SaaS.
- Hospital and academic collaboration contracts: Generates research contracts with hospitals and academic institutions (Samsung Seoul Hospital, Yonsei University Medical Center Industry-Academic Cooperation Foundation, Gangneung National University, The First Affiliated Hospital of Xinxiang Medical University, Chinese hospitals). Likely grant- or milestone-based.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Custom contract / project-based engagement; quote-based |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
ARONTIER product offering
Product offeringCore offering
Arontier is an AI-driven drug discovery company that operates an integrated precision medicine platform combining physics-based modeling with machine learning to design antibodies, protein/peptide binders, peptidomimetics, RNA therapeutics, and small-molecule drugs. The company provides joint research, co-development, and contract research services to pharmaceutical, biotech, hospital, and academic partners, and sells platform access (AD3) along with diagnostic digital pathology products (Arontier PATH, DeepComet).
Product overview
Arontier offers an integrated AI-driven precision medicine platform composed of multiple specialized modules that together cover the full drug discovery pipeline from target identification to candidate design. The platform's foundation rests on REMEDY (multiomics target and drug candidate discovery), which feeds into three designer modules: Small Molecule Designer (for small-molecule drug discovery via generative AI and high-throughput virtual screening including the Docking of Millions system), Protein Designer (for antibody and protein binder design, including AllomorphicANTIBODY and AI-based Deimmunization), and RNA Designer (for personalized neoantigen cancer vaccines). Complementary digital pathology products Arontier PATH (AI tumor microenvironment classifier; MFDS approval in progress) and DeepComet (AI DNA damage analysis) extend the platform into diagnostic and safety applications. The proprietary AD3 platform (beta launched October 2022) serves as the user-facing AI drug development platform integrating these capabilities. Together, these modules position Arontier as a full-stack AI drug discovery company addressing incurable and rare diseases.
Differentiator
Problem solved
Functional benefit
Brands
- REMEDY: AI-based multiomics platform for discovery of novel targets and drug candidates.
- SMALL MOLECULE DESIGNER
- PROTEIN DESIGNER
- RNA DESIGNER
- Arontier PATH
- DeepComet
- AD3
Products and services
- REMEDY Discovery platform that uses multiomics data (transcriptomics, genomics, proteomics) and LINCS-based signature reversal to identify novel drug targets and repurpose existing compounds for new indications. Sold to pharmaceutical, biotech, hospital, and academic research partners.
- Small Molecule Designer AI platform for de novo small-molecule drug discovery combining generative molecular design, high-throughput virtual screening via the Docking of Millions (DoM) system, and medicinal chemistry expertise. For pharmaceutical and biotech R&D partners.
- Protein Designer De novo design platform for antibodies and protein/peptide binders using generative deep learning, protein-protein interaction prediction, molecular dynamics simulations, and AI-based deimmunization. Supports the AllomorphicANTIBODY antibody project. For pharma and biotech R&D teams.
- RNA Designer AI platform for personalized neoantigen cancer vaccine design, with proprietary mRNA design achieving 10x higher expression. For cancer vaccine developers, biotech, and pharma partners.
- Arontier PATH Digital pathology AI biomarker that classifies the tumor microenvironment from hematoxylin and eosin-stained whole-slide histopathology images, supporting cancer-associated fibroblast (CAF) characterization. Used in hospital and clinical research settings; MFDS approval in progress.
- DeepComet AI-powered DNA damage analysis tool using comet assay-based methods for genotoxicity assessment in drug safety evaluation. For pharmaceutical R&D and safety pharmacology teams.
- AD3 AI Drug Development Platform Integrated user-facing AI drug development platform launched in beta in October 2022, providing AI-based drug candidate screening capabilities to pharmaceutical and biotech research partners.
- CAF-based eRNA Target Discovery AI Platform AI platform for cancer-associated fibroblast (CAF)-derived enhancer RNA (eRNA) target discovery, extending multiomics target identification capabilities into cancer therapeutics. Unveiled at AACR 2026.
Quantifiable outcome
- Reduces candidate development time from an industry average of ~5 years to as little as ~1 year
- +4 more outcomes
Companies that use ARONTIER
Customer profileNamed customers19 records
Ideal customer profiles4 records
ARONTIER technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability12 records
Feature14 records
ARONTIER partnerships and signals
Strategic signalPartnerships
22 partnerships are on record, tiered minor and core.
- SynthentaminorArontier and Synthenta are conducting an AI-based small molecule design and synthesis service collaboration.
- Organoid Sciences (오가노이드사이언스)coreOrganoid Sciences and Arontier announced an expansion of AI-based non-clinical evaluation technology collaboration.
- HLB Panagine (HLB파나진)coreHLB Panagine launched a spatial proteome analysis service using Arontier's AI technology, building on HLB Group's incorporation of Arontier AI for diagnostics and new drugs.
- Celltrion Pharm (셀트리온제약)coreAI new drug development company Arontier and Celltrion Pharm entered into a new drug development agreement using Arontier's AI drug development platform.
- PharmAbcinecorePharmAbcine and Arontier announced a partnership to develop an AI-driven antibody-based drug development platform (announced 2025-02-10).
- Spark BiopharmaminorSpark Biopharma is referenced alongside Odyssey Therapeutics and Arontier in the PharmAbcine/Arontier announcement context, for collaboration to develop autoimmune and inflammatory disease drugs using pDOS technology within Odyssey's research strategy (Odyssey raised over USD 700 million in funding).
- Pharmexin (파멥신)corePharmexin is incorporating Arontier's AI technology to build a next-generation antibody development platform.
- Dongkook Pharmaceutical (동국제약)coreDongkook Pharmaceutical and Arontier signed an agreement for joint research on AI-based advanced pharmaceutical development.
- Teragenbio (테라젠바이오)coreTeragenbio and Arontier jointly develop an AI-based personalized cancer vaccine design platform.
- HLB BioStep (HLB바이오스텝)coreHLB BioStep and Arontier signed an agreement for full-scale ('all-directional') cooperation to accelerate AI new drug development.
- Samjin Pharmaceutical (삼진제약)coreSamjin Pharmaceutical entered into an AI-based immune anticancer drug joint research contract with Arontier.
- Gradient Bioconvergence (그래디언트바이오컨버전스)minorGradient Bioconvergence signed a new drug development business agreement with Arontier.
- Aijin (아이진)minorAgreement between Aijin and Arontier to develop AI-based mRNA vaccine.
- K-Medi Hub (케이메디허브)coreArontier and K-Medi Hub are jointly developing AI-based patient-customized innovative new drugs. Subsequent 'new drug candidate discovery' workshop held December 2025.
- Professor Park Jong-min's team, Kangwon National University (박종민 강원대 교수팀)minorArontier signed a joint research and development contract with Professor Park Jong-min's team at Kangwon National University for CAF-targeted new drug development.
- NexEye (넥스아이)minorNexEye and Arontier signed an MOU for joint development of AI-based antibody new drugs.
- Samsung Seoul Hospital (삼성서울병원)coreSamsung Seoul Hospital and Arontier signed an MOU for AI-driven innovative new drug development.
- The First Affiliated Hospital of Xinxiang Medical University (新乡医学院第一附属医院)minorArontier signed a joint new drug research agreement with the First Affiliated Hospital of Xinxiang Medical University (China).
- Chinese hospital partner (中 병원)minorArontier collaborated with a Chinese hospital partner to develop new drugs targeting the tumor microenvironment.
- Yonsei University Medical Center Industry-Academic Cooperation Foundation (연세의료원 산학협력단)coreArontier and Yonsei University Medical Center's Industry-Academic Cooperation Foundation signed a joint new drug research agreement.
- Future Medicine (퓨쳐메디신)coreJoint research on immune anticancer drugs applying Arontier's AI new drug development platform; subsequent collaboration in May 2023 to apply AI to nucleoside-based new drug development.
- Seoul National University, Ulsan University, and KAIST (Korea Advanced Institute of Science and Technology)coreArontier was selected as the lead company for the 'Drug Candidate Discovery' area of the Korean national 2019 AI Drug Development Platform Construction Project, with joint research partners Seoul National University, Ulsan University, and KAIST. Total per-project funding ~11.25 billion KRW over 3 years (2+1).
Scale indicators10 records
Recent moves6 records
Expansion highlights8 records
ARONTIER competitors and assessment
Company assessmentDirect peers
- XtalPi: Asia-based AI + physics-driven drug discovery platform with comparable small-molecule design, virtual screening, and CRO partnership model; directly competes for the same Asian pharma enterprise customers Arontier serves.
- Insilico Medicine: End-to-end AI drug discovery company with target identification (PandaOmics), generative chemistry (Chemistry42), and clinical assets — directly comparable to Arontier's REMEDY-to-RNA-Designer pipeline and to its claim of compressing 5-year timelines to ~1 year.
- Recursion Pharmaceuticals: AI-driven drug discovery combining high-throughput biology with ML for target and candidate identification across multiple modalities. Comparable in modality breadth, multi-pharma partnership model, and digital pathology-adjacent phenomics.
- BenevolentAI: AI platform for target identification and drug discovery with focus on multiomics and knowledge graphs; analogous to Arontier's REMEDY (LINCS-based signature reversal) target-discovery approach.
- Standigm: Korean AI drug discovery company offering end-to-end target identification, lead generation, and candidate design — a direct domestic peer competing for the same Korean pharma partners and national R&D programs as Arontier.
- Atomwise: AI small-molecule discovery platform (AtomNet) for hit identification and lead optimization through virtual screening. Directly comparable to Arontier's Small Molecule Designer and DoM offering.
- Schrödinger: Physics-based plus ML drug discovery platform with comparable small-molecule virtual screening and protein-ligand binding prediction capabilities. Arontier's DoM, AK-Score2 and V-Dock mirror Schrödinger LiveDesign and FEP+ workflows; both target pharma/biotech enterprise customers.
Emerging players
- AIGEN Sciences: Korean AI-driven drug discovery startup focused on generative chemistry and protein design; an emerging domestic peer with partial overlap in small-molecule and protein-ligand modeling capabilities.
- Adagene: AI-driven antibody discovery platform (POWER-based) with comparable antibody design and deimmunization capabilities to Arontier's Protein Designer and AllomorphicANTIBODY module.
- Pharos iBio: Korean AI-target-discovery biotech using omics and knowledge graphs; comparable to Arontier's REMEDY multiomics target discovery module and competing for the same Korean pharma collaborations.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
ARONTIER social profiles
Digital presenceARONTIER compliance and trust
Trust signalCompliance1 record
ARONTIER financial estimates
Financial estimateRevenue estimate
Valuation estimate
ARONTIER leadership team
Management profileNumber of profiles
Profiles2 records
ARONTIER subsidiaries and ownership
Company hierarchySubsidiaries1 record
ARONTIER funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ARONTIER M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ARONTIER
What does ARONTIER do?
Arontier is an AI-driven drug discovery company that operates an integrated precision medicine platform combining physics-based modeling with machine learning to design antibodies, protein/peptide binders, peptidomimetics, RNA therapeutics, and small-molecule drugs. The company provides joint research, co-development, and contract research services to pharmaceutical, biotech, hospital, and academic partners, and sells platform access (AD3) along with diagnostic digital pathology products (Arontier PATH, DeepComet).
Is ARONTIER a public or private company?
ARONTIER is a private company. It is classified as venture growth investor backed and is currently operating.
When was ARONTIER founded?
ARONTIER was founded in 2018. It employs 11 to 50 people.
Where is ARONTIER based?
ARONTIER is headquartered in Seocho, South Korea, in the Asia region.
How does ARONTIER make money?
Five revenue lines are on record. Equity investment / capital raise is the primary driver. The others are government R&D grants and national project funding, joint research and co-development contracts with pharma/biotech, platform-as-a-Service / contract research services and hospital and academic collaboration contracts.
Who are ARONTIER's main competitors?
Direct peers on record are XtalPi, Insilico Medicine, Recursion Pharmaceuticals, BenevolentAI, Standigm, Atomwise and Schrödinger. Emerging players are AIGEN Sciences, Adagene and Pharos iBio.
Does ARONTIER have an API?
No public API is recorded for ARONTIER.
What industry is ARONTIER in?
ARONTIER's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714.